<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03256903</url>
  </required_header>
  <id_info>
    <org_study_id>MR311-3502</org_study_id>
    <nct_id>NCT03256903</nct_id>
  </id_info>
  <brief_title>Methoxyflurane vs Standard Analgesic Treatment for Trauma Pain in Spanish Emergency Units</brief_title>
  <acronym>InMEDIATE</acronym>
  <official_title>Open Randomized Clinical Trial to Compare Pain Relief Between Methoxyflurane and Standard of Care for Treating Patients With Trauma Pain in Spanish Emergency Units.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Pharmaceuticals S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Clinical Research Network - CAIBER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Society for Emergency Medicine (SEMES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mundipharma Pharmaceuticals S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to compare pain relief between methoxyflurane and any analgesic treatment used
      in usual clinical practice, in patients with trauma and associated pain, treated in Spanish
      emergency units.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, randomized clinical trial to compare emergency pain relief between methoxyflurane and
      standard of care in patients with trauma and associated pain, treated in Spanish emergency
      units.

      Methoxyflurane is a fluorinated ethyl methyl ether, with the chemical name
      2:2-dichloro-1:1-difluoroethyl methyl ether. It belongs to the fluorinated hydrocarbon group
      of volatile anaesthetics. It is inhaled as a vapour at low (sub-anaesthetic) concentrations
      to achieve an analgesic effect for the management of pain.

      In Europe countries, where methoxyflurane is already marketed, it is indicated for emergency
      relief of moderate to severe pain in conscious adult patients with trauma and associated
      pain.

      On the other hand, current clinical practice includes a variety of analgesic agents, with the
      choice of which to employ based on consideration of the risk-benefit factors of each class of
      drug, as well as the type of pain, its severity, and the risk of adverse effects.

      The main objective of this study is to assess Methoxyflurane's significant advantage in terms
      of anaglesic effectiveness, as it is known as a rapidly acting, non-narcotic analgesic for
      the treatment of emergency pain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase IIIb open randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>At baseline, 3, 5, 10, 15 and 20 minutes from STA</time_frame>
    <description>Change in mean pain intensity over 20 min from start of administration (STA) and time to first pain relief, measured by numeric scale (0-10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesia effectiveness</measure>
    <time_frame>Change from baseline to 3, 5, 10, 15, 20 and 30 min</time_frame>
    <description>Difference between arms related to analgesia effectiveness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesia speed of action</measure>
    <time_frame>From time of randomization up to 20 minutes</time_frame>
    <description>Difference between arms related to speed of action of analgesia for all patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety for patients with severe pain, treated with second or third step analgesics</measure>
    <time_frame>Up until 14 days from STA</time_frame>
    <description>Difference between arms related to safety for patients with severe pain (NRS &gt;7), treated with second or third step analgesics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-averaged summed pain intensity difference 15 min after STA</measure>
    <time_frame>from baseline to 3, 5, 10 and 15 minutes post dose</time_frame>
    <description>Patient-averaged summed pain intensity difference 15 min after STA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Responders</measure>
    <time_frame>from baseline to 20 minutes post dose</time_frame>
    <description>Pain Responders (with &gt;30% pain relief compared to baseline) at 20 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigators and patients satisfaction</measure>
    <time_frame>30 min from start of administration</time_frame>
    <description>Investigators and patients satisfaction measured as convenience, treatment efficacy and adverse events, using NRS scales (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and investigators' fulfillment of expectations</measure>
    <time_frame>30 min from start of administration</time_frame>
    <description>Patient and investigators' fulfillment of expectations, measured with a 5 items Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' Global Impression of Change with the treatments</measure>
    <time_frame>Up until 30 minutes from STA</time_frame>
    <description>Patients' Global Impression of Change with the treatments, measured using a 7 items Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment cost of pain relief</measure>
    <time_frame>Up until 60 minutes from randomization</time_frame>
    <description>Treatment cost of pain relief, measured considering use of fungible material; need of nurse to administer iv treatments; time to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety rates of treatment emergent adverse events</measure>
    <time_frame>Up until 14 days from STA</time_frame>
    <description>Safety rates of treatment emergent adverse events (TEAE) in both arms, including alterations in biochemical and blood count.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Acute Pain Due to Trauma</condition>
  <arm_group>
    <arm_group_label>Methoxyflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SoC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyflurane</intervention_name>
    <description>Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.</description>
    <arm_group_label>Methoxyflurane</arm_group_label>
    <other_name>No other interventions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain</description>
    <arm_group_label>Standard of Care (SoC)</arm_group_label>
    <other_name>No other interventions</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients: ≥ 18 years of age

          -  Moderate to severe pain (NRS 0-10; &gt;=4) secondary to trauma

          -  Without anticipating surgery due to the trauma, requiring hospitalization (hospital
             stay 12h)

          -  Conscious patient.

          -  Giving informed consent in writing

        Exclusion Criteria:

          -  Hypersensitivity to methoxyflurane (MEOF) or any fluorinated anaesthetic.

          -  Malignant hyperthermia: patients with known or genetically susceptible to malignant
             hyperthermia or a history of severe adverse reactions in either patient or relatives.

          -  Patients who have a history of showing signs of liver damage after previous MEOF use
             or halogenated hydrocarbon anaesthesia

          -  Known clinically significant renal impairment

          -  Known pregnant or likely to be pregnant women at the time of inclusion.

          -  Clinically evident cardiovascular instability

          -  Clinically evident respiratory depression

          -  Patients taken any analgesic for the traumatic pain before inclusion

          -  Altered level of consciousness due to any cause, including head injury, drugs or
             alcohol

          -  Degenerative diseases, mental illness or other conditions that could affect ability of
             valuing pain intensity

          -  Patients to be unable to understand the purpose of the study and perform
             self-assessments, following investigator's criteria.

          -  Participation in another clinical trial within 30 days prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Borobia, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>La Paz University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Posada Novoa</last_name>
    <phone>0034 91 727 7000</phone>
    <phone_ext>42485</phone_ext>
    <email>maria.posada@idipaz.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundación Pública Urxencias Sanitarias de Galicia-061</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Sánchez Santos, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Viladecans</name>
      <address>
        <city>Viladecans</city>
        <state>Barcelona</state>
        <zip>08840</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Arranz Betegón, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Bierzo</name>
      <address>
        <city>Ponferrada</city>
        <state>León</state>
        <zip>24404</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Ramón Casal, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Capilla, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Amador Barciela, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gernika-Lumo</name>
      <address>
        <city>Gernika-Lumo</city>
        <state>Vizcaya</state>
        <zip>48300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aitor Odiaga, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emergencias Osakidetza</name>
      <address>
        <city>Gernika-Lumo</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amaia Etxebarria Gulias, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Llorens Soriano, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>María Corell, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen del Arco, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cesareo Fernández Alonso, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>José Antonio Valle Cruz, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUMMA - Comunidad de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28045</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Cid Dorribo, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Carballo Cardona, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Pérez Torres, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Campo Grande</name>
      <address>
        <city>Valladolid</city>
        <zip>47006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio García Collado, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Zamora</name>
      <address>
        <city>Zamora</city>
        <zip>49022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anselma Fernández, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Alberto M. Borobia</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Methoxyflurane</keyword>
  <keyword>emergency</keyword>
  <keyword>trauma pain</keyword>
  <keyword>inhaled analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Methoxyflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

